Documented potential for drug candidate with characteristics like WP1122 to reverse immune suppression HOUSTON, ...
Helsinn Group announces the appointment of Paul Rittman as Chief Executive Officer, Helsinn Therapeutics ...
Agreement accelerates development of Adaptimmune’s lead T-cell therapy targeting NY-ESO-1 toward pivotal trialsCreates opportunity ...
